Effectiveness of Secukinumab in the treatment of moderate–severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real‐life setting

Secukinumab in the Treatment of Moderate-to-Severe Hidradenitis Suppurativa: Results of an Open-Label Trial

(2020) Rachel G. Casseres et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Effectiveness of secukinumab in Hidradenitis Suppurativa : an open study (20 cases)

(2020) Z. Reguiaï et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance

(2020) John W. Frew et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Open‐label, investigator‐initiated, single‐site exploratory trial evaluating secukinumab, an anti‐interleukin‐17A monoclonal antibody, for patients with moderate‐to‐severe hidradenitis suppurativa

(2019) L. Prussick et al.   BRITISH JOURNAL OF DERMATOLOGY

Mechanisms of Inflammation in Neutrophil-Mediated Skin Diseases

(2019) Angelo V. Marzano et al.   Frontiers in Immunology

Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease

(2017) Megan Hohenberger et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Increased interleukin (IL)-17 serum levels in patients with hidradenitis suppurativa: Implications for treatment with anti-IL-17 agents

(2017) Łukasz Matusiak et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY